These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36431015)

  • 1. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Pérez-Gil A; Font-Ugalde P; Galán-Gutiérrez M
    Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36431015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.
    Galan-Gutierrez M; Font-Ugalde P; Padilla L; Hernandez-Montoya C; Godoy D; Armario-Hita JC; Ruiz-Villaverde R
    Int J Dermatol; 2023 May; 62(5):700-706. PubMed ID: 36495585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
    Martorell A; Santos-Alarcón S; Sahuquillo-Torralba A; Rivera-Díaz R; Belinchón-Romero I; Ruiz-Genao D; Romero-Maté A; Ruiz-Villaverde R; Ferran-Farrés M; Gallardo-Hernández F; Almenara-Blasco M; Suarez-Perez JA; González-Cantero Á; Martínez-Lorenzo E; Fernández-Armenteros JM; Del Alcázar-Viladomiu E; García-Latasa J; Rocamora-Durant V; Ara-Martín M; Mateu-Puchades A; Llamas-Velasco M; Vilarrasa E; Velasco-Pastor M; De la Cueva P; Carrascosa JM; Magdaleno-Tapial J
    Actas Dermosifiliogr; 2024 Mar; ():. PubMed ID: 38452889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.
    Gargiulo L; Ibba L; Pavia G; Vignoli CA; Piscazzi F; Valenti M; Sanna F; Perugini C; Avagliano J; Costanzo A; Narcisi A
    Dermatol Ther (Heidelb); 2022 Oct; 12(10):2309-2324. PubMed ID: 36063283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
    Borroni RG; Malagoli P; Gargiulo L; Valenti M; Pavia G; Facheris P; Morenghi E; Di Corteranzo IG; Narcisi A; Ortoncelli M; Dapavo P; Costanzo A
    Acta Derm Venereol; 2021 Nov; 101(11):adv00605. PubMed ID: 34596230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
    J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
    Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.
    Gkalpakiotis S; Cetkovska P; Arenberger P; Dolezal T; Arenbergerova M; Velackova B; Fialova J; Kojanova M;
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1345-1355. PubMed ID: 34089479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain).
    Ruiz-Villaverde R; Rodriguez Fernandez-Freire L; Font-Ugalde P; Galan-Gutierrez M
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
    Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
    J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Amoruso F; Argenziano G; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Maurelli M; Megna M; Orsini D; Sampogna F; Travaglini M; Valenti M; Costanzo A; Narcisi A
    J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
    Thaçi D; Eyerich K; Pinter A; Sebastian M; Unnebrink K; Rubant S; Williams DA; Weisenseel P
    Br J Dermatol; 2022 Jan; 186(1):30-39. PubMed ID: 33991341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
    Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
    Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.